XOMA Ltd.

Corporate Snapshot

XOMA Ltd. ("the Company") is a biopharmaceutical company in the field of therapeutic antibody discovery and development. The Company discovers, develops, and manufactures antibodies and other recombinant protein biologics for commercialization in several therapeutic areas, including immunological and inflammatory disorders and cancer. Along with developing proprietary products, XOMA enters into collaborative programs with other companies, leveraging its infrastructure to broaden its product pipeline, diversify development risk, and share the financial burden of drug development. XOMA has a royalty interest in an approved drug, RAPTIVA®, a humanized therapeutic monoclonal antibody (MAb) developed to treat immune system disorders. RAPTIVA® is the first U.S. Food and Drug Administration (FDA)-approved biologic therapy designed to provide long-term control of chronic moderate-to-severe plaque psoriasis. Genentech, Inc. (DNA-NYSE) markets RAPTIVA® in the U.S. and Serono S.A. (SRA-NYSE), Genentech's international marketing partner for RAPTIVA®, promotes the drug outside the U.S. (except Japan). XOMA also has a pipeline of products in almost all stages of evaluation. In oncology, Chiron Corporation (now Novartis AG, [NVS-NYSE]) and XOMA have advanced CHIR-12.12 (to be re-named HCD 122), an anti-CD40 MAb intended to treat B-cell malignancies, into Phase I for two indications. XOMA is collaborating with Lexicon Genetics, Inc. (LEXG-NASDAQ) to develop a metabolic MAb to treat Type II diabetes and obesity, and has launched a wide-ranging collaboration with Schering-Plough Corporation (SGP-NYSE) for therapeutic MAb discovery and development. Other drugs in development include NEUPREX®, an injectable formulation of rBPI21, (a modified recombinant fragment of human bactericidal/permeability-increasing protein [BPI]) in or soon to be in investigator-sponsored studies for pediatric open-heart surgery (POHS), burns, bone marrow/stem cell transplant, and potentially other applications, including biodefense. XOMA’s antibody technology platform includes proprietary bacterial cell expression (BCE) technology, a Human Engineering™ method for creating human-like antibodies and, through BCE cross-licenses, access to seven leading phage display antibody discovery libraries. Two antibody development and manufacturing contracts also earn revenues.